Cargando…

Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score

BACKGROUND: Recently, several randomized controlled trials (RCTs) investigated immunotherapy-based regimens versus chemotherapy alone in patients with advanced esophageal squamous cell carcinoma (ESCC). Here we conducted a systematic review and meta-analysis on the efficacy and activity of programme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leone, A.G., Petrelli, F., Ghidini, A., Raimondi, A., Smyth, E.C., Pietrantonio, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804258/ https://www.ncbi.nlm.nih.gov/pubmed/35093742 http://dx.doi.org/10.1016/j.esmoop.2021.100380

Ejemplares similares

Predictive role of microsatellite instability for of PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials
por: Pietrantonio, F., et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Distribution of residual tumors in esophageal squamous cell carcinoma after neoadjuvant PD-1 blockade combined with chemotherapy
por: Jiang, Dongxian, et al.
Publicado: (2023)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
por: Yang, Jiqiao, et al.
Publicado: (2019)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

PD‐1/PD‐L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta‐analysis focus on PD‐L1 expression level
por: Jin, Zixian, et al.
Publicado: (2023)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups
por: Yap, Dominic Wei Ting, et al.
Publicado: (2022)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Is PD-1 blockade a potential therapy for HBV?
por: Féray, Cyrille, et al.
Publicado: (2019)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
por: Lin, Weimin, et al.
Publicado: (2018)

PD-1 Blockade in Anaplastic Thyroid Carcinoma
por: Capdevila, Jaume, et al.
Publicado: (2020)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
por: Kamada, Takahiro, et al.
Publicado: (2019)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
por: Zhuang, Yuan, et al.
Publicado: (2020)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
por: Chen, Meng, et al.
Publicado: (2022)

The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma
por: van Laarhoven, Hanneke W.M., et al.
Publicado: (2023)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
por: Jimbu, Laura, et al.
Publicado: (2021)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
por: Hirsch, Laure, et al.
Publicado: (2018)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0v2qc6efu9pak13gqna5hmr3fg